We develop antibody-based therapies targeting IL1RAP

See our pipeline

Our goal is to treat cancer as well as inflammatory and autoimmune diseases

See our clinical program

Strong results provide support for our development programs

See our company presentation

Aktiedagarna

Aktiedagarna

CEO Göran Forsberg presents at Aktiedagarna in Stockholm

Watch the presentation here

2024-06-28 Intervju with Redeye

Interview with CEO Göran Forsberg regarding new results in pancreatic cancer

Watch the interview in Swedish here

2024-06-28 Intervju with Redeye

2024-03-28 Interview with Redeye

2024-03-28 Interview with Redeye

Interview with CEO Göran Forsberg regarding the significance of Avalo's financing and development of IL-1beta antibody

Watch the interview in Swedish here

Press releases

2024-09-30 (R) Cantargia reports start of multiple dosing part in CAN10 phase 1 clinical trial

2024-09-25 (R) Cantargia presents new results at EADV 2024 highlighting the potential of CAN10 treatment in dermatology

2024-09-14 (R) Cantargia presents positive results at ESMO Congress 2024 showing benefit of nadunolimab combination therapy in cancer after relapse on PD1-inhibitors

(R) = Regulatory press releases

Analysis

2024-09-09, Redeye analysis of Cantargia

2024-03-18, Redeye analysis of Cantargia

2024-02-21, Redeye analysis of Cantargia

2023-11-13, Redeye analysis of Cantargia

Current corporate presentation

Download the corporate presentation as PDF

Other presentations

2024-09-18, Video Presentation, Aktiedagarna Stockholm (In Swedish)

2024-09-18, Presentation, Aktiedagarna Stockholm

2024-04-10, Video, lnvesting in Oncology Forum 2024

2024-02-28, Presentation, Sachs 17th Annual European Life Sciences CEO Forum

2024-01-24, Video, Redeye Fight Cancer Event 2024